Advertisement
In the United States, narcotic pain relievers have fueled a dangerousepidemic. One in five teens has abused a prescription pain medication(1) andemergency room visits associated with these drugs have increased 163 percentsince 1995(2). The situation has created barriers to access for patientssuffering from real pain: Doctors are more reticent to prescribe opioids, andregulators have refused to allow new analgesics on the market unless they havethe highest forms of abuse deterrence measures in place.
Advertisement
But Tris Pharma's NoBuse(TM) technology allows companies to provide painrelief responsibly. "In the current environment where opioid abuse has becomesuch a problem, companies must first consider safeguarding their drugs if theywant to reach patients in need," says Ketan Mehta, CEO and Founder of TrisPharma. "There's no reason for patients to suffer needlessly when NoBuse(TM)provides such an effective option for abuse prevention."
There is a perception that conventional sustained release formulations areless prone to abuse then immediate-release formulations. However, users caneasily extract the full 12-24 hour dose from existing sustained-releasepreparations for immediate consumption and then snort, swallow, or inject it-all of which provides users a "high" and which can be extremely dangerous whenlarger than intended doses are taken.
The NoBuse(TM) delivery system is engineered to prevent abuse on aphysical level without the need for additional ingredients. NoBuse(TM) employsa technique where the drug is complexed to very fine polymeric particles andcoated with a highly flexible non-breakable film resulting in particles thatare extremely difficult to extract drug from-even after crushing the tablet ordissolving it in alcohol.
"Abuse of prescription drugs is a fast-growing problem-being able to limitthis liability is a real benefit to society," says Thomas Newton, MD,Professor of Psychiatry at the Baylor College of Medicine. "Other methods canbe breached-but the data for NoBuse(TM) shows that it is virtually impossiblefor abusers to get around. I also like the fact that the abuse deterrence isnot contingent on the patient being forced to take added active ingredientssuch as the antagonist naloxone. The vast majority of patients aren't abusersand there is no reason for them to ingest an additional drug they don't need."
The technology works across a range of oral dosage forms includingtablets, liquid suspensions, orally disintegrating tablets, and drug strips.It can also be used to formulate an immediate-release product with a built-inabuse deterrent. In doing so, Tris Pharma's NoBuse(TM) technology providesimportant value and a competitive advantage against competing deliverytechnologies.
About Tris Pharma, Inc.
Tris Pharma, Inc. is a specialty drug delivery technology company. Trisspecializes in controlled release dosage forms for liquid, solid and orallydisintegrating tablets; abuse-deterrent technology; and bioavailabilityenhancement of poorly absorbed drugs. Through its pharma partners, Tris hasmore than 30 products in development, submission or on market. Tris' researchand manufacturing facilities are located in central New Jersey, USA. For moreinformation, please visit www.trispharma.com
(1) Partnership for a Drug Free America
(2) "Prescription for Danger," produced by the Office of National DrugControl Policy, January 2008
SOURCE Tris Pharma
